Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD264 APC

Anti-Hu CD264 APC

Regulatory status

RUO

Antigen

CD264

Clone

TRAIL-R4-01

Format

APC

Reactivity

Human

Application

FC (QC tested)

Excitation laser

red (633 nm)

Variant

0.1 mg

1A-519-C100

In stock

220.00 USD

Variant

0.1 mg

1A-519-C100

In stock

220.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The antibody TRAIL-R4-01 reacts with an extracellular epitope of TRAIL-R4, a 42 kDa transmembrane protein expressed on various blood cells.

Workshop

HLDA IX

Application

FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 1-5 μg/ml.

Reactivity

Human

Immunogen

TRAIL-R4 (aa 1-210) - hIgGhc fusion protein

Concentration

0.1 mg/ml

Preparation

Purified antibody is conjugated with activated allophycocyanin (APC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

TNFRSF10D, DcR2, TRUNDD, TRAILR4

Antigen description

TRAIL-R4 (CD264, TR4, DcR2, TRUNDD), expressed mainly on CD8+ and NK cells, belongs to receptors of TRAIL, a TNF-like membrane toxic protein that induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R4, however, contains partially truncated death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by impairment death-inducing signaling complex (DISC) processing. TRAIL-R4 interacts with death receptor 5 (DR5) in the native DISC in a TRAIL-dependent manner and prevents its corecruitment with death receptor 4 (DR4).

Entrez Gene ID 8793

UniProt ID Q9UBN6

Flow cytometry surface staining pattern of CD264 transfected HEK-293 cells using anti-human CD264 (TRAIL-R4-01) APC (concentration in sample 1,67 μg/ml).

Separation of cells stained using anti-human CD264 (TRAIL-R4-01) APC antibody (concentration in sample 1,67 μg/ml, red-filled) from CD264 cells stained using mouse IgG1 isotype control (MOPC-21) APC antibody (concentration in sample 1,67 μg/ml, black-dashed) in flow cytometry analysis (surface staining) of CD264 transfected HEK-293 cell suspension.

General references:

Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol Oncol Res. 2007;13(4):290-4.
PubMed

Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39(7-8):1462-75.
PubMed

Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006 Oct;26(19):7046-55.
PubMed

Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 May 25;5(1):54.
PubMed

Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18099-104.
PubMed